Business Segments · Net Income Loss
Business Segments — Net Income Loss
Polaryx Therapeutics, Inc. Business Segments — Net Income Loss increased by 49.6% to -$2.54M in Q1 2026 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
A narrowing loss signals progress toward commercialization or improved cost management, while a widening loss indicates increased investment or rising operational costs.
Detailed definition
This metric represents the bottom-line financial performance of the lysosomal storage disorders segment, calculated by s...
Peer comparison
Commonly used by investors to evaluate the 'burn rate' of specific therapeutic pipelines in clinical-stage biotech firms.
Metric ID:
plyx_segment_lysosomal_storage_disorders_net_income_lossHistorical Data
2 periods
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | -$5.05M | -$2.54M |
| QoQ Change | — | +49.6% |
| YoY Change | — | +49.6% |
Range-$5.05M – -$2.54M
Avg YoY Growth+49.6%
Median YoY Growth+49.6%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Polaryx Therapeutics, Inc. 's business segments — net income loss?
- Polaryx Therapeutics, Inc. (PLYX) reported business segments — net income loss of -$2.54M in Q1 2026.
- What does business segments — net income loss mean?
- The net profit or loss generated by the lysosomal storage disorders business segment.